Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01859351

Enrollment

Registered

2013-05-21

Start date

2013-07-31

Completion date

2014-04-30

Last updated

2014-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumours

Brief summary

The purpose of this study is to test the safety of escalating doses of the novel PI3K inhibitor WX-037 and to explore its effectiveness in combination with WX-554 which targets mitogen activated protein kinase (MEK1 and MEK2). Preclinical evidence indicates that these two novel compounds could provide targeted inhibition of both pathways to block tumour growth.

Interventions

DRUGWX-037

DRUGWX-554

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with advanced, metastatic and/or progressive solid tumors for whom there is no effective standard therapy available (for part 2 in addition patients for whom their PI3K pathway is deregulated) * Evaluable or measurable disease * Has normal organ function; is no greater than 2 on the ECOG performance scale * Negative hCG test in women of childbearing potential

Exclusion criteria

* History of diabetes requiring daily medication or history of grade 3 or more fasting hyperglycemia * Patients with major surgery, radiotherapy, or immunotherapy within 4 weeks of starting the study * Clinical significant, unresolved toxicity from previous anti-cancer therapy * Patients who previously received a MEK inhibitor (for combination part only) * Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs * Known medical history of retinal vein occlusion, intraocular pressure greater than 21 mm Hg or patient considered at risk of retinal vein thrombosis (combination part only) * Known HIV positivity or active hepatitis B or C infection * History of clinically significant cardiac condition

Design outcomes

Primary

Measure	Time frame
Incidence of Dose limiting toxicities	during cycle 1 (21days) of treatment with WX-037
Incidence of Dose Limiting toxicities	during cycle 1 (21 days) of treatment with WX-037 and WX-554

Secondary

Measure	Time frame
Number of patients with adverse Events and serious adverse events	from cycle 1 day 1 until treatment discontinuation, an estimated average of 18 weeks
Assessment of PK variables, peak plasma concentration (Cmax), area under the curve (AUC)	two PK profiles in cycle 1
Determination of PD markers; changes from baseline in biomarkers of pathway inhibition	predose until treatment discontinuation, an estimated average of 18 weeks

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026